Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D E Mager

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Journal of Clinical Pharmacology|February 6, 2013
Population pharmacokinetics and dose optimization of mycophenolic acid in HCT recipients receiving oral mycophenolate mofetilH Li, D E Mager, B M Sandmaier, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 15, 2016
Bridging Sunitinib Exposure to Time-to-Tumor Progression in Hepatocellular Carcinoma Patients With Mathematical Modeling of an Angiogenic BiomarkerS Ait-Oudhia, D E Mager, V Pokuri, et al.
The Journal of Urology|June 24, 1999
Correlates of dissatisfaction with treatment in patients with prostate cancer diagnosed through screeningG F Carvalhal, D S Smith, C Ramos, et al.
Clinical Pharmacology and Therapeutics|September 13, 2012
Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancerV L Chudasama, F Schaedeli Stark, J M Harrold, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|December 31, 2009
Pharmacokinetics and metabolism of (R,R)-methoxyfenoterol in ratD Siluk, D E Mager, H S Kim, et al.
Clinical Pharmacology and Therapeutics|August 24, 2007
Physical and cognitive performance and burden of anticholinergics, sedatives, and ACE inhibitors in older womenY-J Cao, D E Mager, E M Simonsick, et al.
Cancer Chemotherapy and Pharmacology|April 28, 2006
A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancerR O'Connor, M O'Leary, J Ballot, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Journal of Clinical Pharmacology|February 6, 2013
Population pharmacokinetics and dose optimization of mycophenolic acid in HCT recipients receiving oral mycophenolate mofetilH Li, D E Mager, B M Sandmaier, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 15, 2016
Bridging Sunitinib Exposure to Time-to-Tumor Progression in Hepatocellular Carcinoma Patients With Mathematical Modeling of an Angiogenic BiomarkerS Ait-Oudhia, D E Mager, V Pokuri, et al.
The Journal of Urology|June 24, 1999
Correlates of dissatisfaction with treatment in patients with prostate cancer diagnosed through screeningG F Carvalhal, D S Smith, C Ramos, et al.
Clinical Pharmacology and Therapeutics|September 13, 2012
Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancerV L Chudasama, F Schaedeli Stark, J M Harrold, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|December 31, 2009
Pharmacokinetics and metabolism of (R,R)-methoxyfenoterol in ratD Siluk, D E Mager, H S Kim, et al.
Clinical Pharmacology and Therapeutics|August 24, 2007
Physical and cognitive performance and burden of anticholinergics, sedatives, and ACE inhibitors in older womenY-J Cao, D E Mager, E M Simonsick, et al.
Cancer Chemotherapy and Pharmacology|April 28, 2006
A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancerR O'Connor, M O'Leary, J Ballot, et al.
Pageof 3